NCT06983756Not yet recruiting
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
Source: ClinicalTrials.gov · Last updated 21 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 66 (estimated)
- First submitted
- 14 May 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- Fayoum University
- Diseases
- Chronic kidney disease
- NCT number
- NCT06983756
What you commit to
- Study type: Observational
- Planned participants: 66
- From 1 Jun 2025 to the primary completion date, 1 Dec 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.
- Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.
- Patients with infection or autoimmune diseases.
Who the study is looking for
- Patients (and replacements) will be randomly selected by a raffle.
- All participants should be 18 years of age or older and agree to participate in the study after due clarification.
- Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.